Vitamin D: studied health effects
What vitamin D studies showed about fractures, fatigue, depression symptoms and cognitive tests.
Key points
- In adults not selected for deficiency, 2,000 IU D3 daily over five years did not reduce fracture frequency compared with placebo. Fracture protection should not be expected from this regimen in this group. [1] See the evidence 1
- In young adults with fatigue and low vitamin D, 72% reported improvement over four weeks after a single 100,000 IU D3 dose versus 50% with placebo. Replenishment may help reduce fatigue when vitamin D is low; 100,000 IU was the studied dose, not a self-administration regimen. [2] See the evidence 1
- In adults aged 50 and over without significant depression symptoms at baseline, 2,000 IU D3 daily over five years did not reduce the risk of depression or significant symptoms compared with placebo. An effect on preventing these symptoms in this group was not shown. [3] See the evidence 1
- In adults aged 60 and over, 2,000 IU D3 daily over two to three years did not improve memory and thinking test results compared with placebo. Improvement in these measures should not be expected from this regimen. [4] See the evidence 1
Practical guide
Please double-check the conclusions and consider your own circumstances when choosing a supplement.
The effect of vitamin D depends on the goal and group studied. Fatigue, fractures and other outcomes require separate comparisons.
Studied effects of vitamin D
Why these conclusions
Fractures, fatigue and other outcomes
The fracture study included men aged 50 and over and women aged 55 and over without selection by vitamin D level. Fracture frequency over five years was approximately the same with 2,000 IU D3 daily and placebo. [1]
In 120 adults with fatigue and 25(OH)D below 20 ng/mL, fatigue decreased more over four weeks after a single 100,000 IU D3 dose than with placebo. This is the studied dose, not a self-administration regimen. [2]
In adults aged 50 and over without clinically significant depression symptoms at baseline, the risk of depression or significant symptoms over five years was approximately the same with 2,000 IU D3 daily and placebo. [3]
In adults aged 60 and over, cognitive test results changed by approximately the same amount over two to three years with 2,000 IU D3 daily and placebo. [4]
Over five years, fractures occurred approximately as often in adults taking 2,000 IU vitamin D3 daily as with placebo. Participants were recruited regardless of vitamin D level.
| Parameter | Data |
|---|---|
| Result | Over five years, fractures occurred approximately as often in adults taking 2,000 IU vitamin D3 daily as with placebo. Participants were recruited regardless of vitamin D level. |
| Participants | 25,871 adults, men aged 50 and over and women aged 55 and over; not selected for vitamin D deficiency |
| Form | D3, cholecalciferol |
| Dose | 2,000 IU (50 µg) daily |
| Dose basis | 2,000 IU (50 µg) daily |
| Comparison | Placebo; omega-3 was randomised separately |
| Duration | Median follow-up 5.3 years |
| Confidence | 3/4: Precision: the estimate was considered sufficiently precise for this specific comparison; no additional downgrade on this basis. Consistency: no substantial inconsistency was identified for this specific comparison or it was described in one trial; no additional downgrade on this basis. Applicability to the stated group: the conclusion applies to the stated participants and measured outcome; no additional downgrade on this basis. Potential publication bias: publication bias for this specific outcome was assessed only to a limited extent; no additional downgrade on this basis. Study methods: methodological limitations and incomplete formal assessment reduce confidence. |
| Volume of evidence | 1 trial |
| Sources | [1] |
Over five years, the risk of depression or significant symptoms with 2,000 IU vitamin D3 daily was approximately the same as with placebo.
| Parameter | Data |
|---|---|
| Result | Over five years, the risk of depression or significant symptoms with 2,000 IU vitamin D3 daily was approximately the same as with placebo. |
| Participants | 18,353 adults aged 50 and over without clinically significant depression symptoms at baseline |
| Form | D3, cholecalciferol |
| Dose | 2,000 IU (50 µg) daily |
| Dose basis | 2,000 IU (50 µg) daily |
| Comparison | Placebo; omega-3 was randomised separately |
| Duration | Median treatment 5.3 years |
| Confidence | 3/4: Precision: the estimate was considered sufficiently precise for this specific comparison; no additional downgrade on this basis. Consistency: no substantial inconsistency was identified for this specific comparison or it was described in one trial; no additional downgrade on this basis. Applicability to the stated group: the conclusion applies to the stated participants and measured outcome; no additional downgrade on this basis. Potential publication bias: publication bias for this specific outcome was assessed only to a limited extent; no additional downgrade on this basis. Study methods: methodological limitations and incomplete formal assessment reduce confidence. |
| Volume of evidence | 1 trial |
| Sources | [3] |
In adults aged 60 and over, cognitive test results changed by approximately the same amount over two to three years with 2,000 IU vitamin D3 daily and placebo.
| Parameter | Data |
|---|---|
| Result | In adults aged 60 and over, cognitive test results changed by approximately the same amount over two to three years with 2,000 IU vitamin D3 daily and placebo. |
| Participants | 3,424 participants in the telephone and 794 in the in-person substudy, aged 60 and over |
| Form | D3, cholecalciferol |
| Dose | 2,000 IU (50 µg) daily |
| Dose basis | 2,000 IU (50 µg) daily |
| Comparison | Placebo; omega-3 was randomised separately |
| Duration | Mean 2.8 and 2.0 years in the two substudies |
| Confidence | 3/4: Precision: the estimate was considered sufficiently precise for this specific comparison; no additional downgrade on this basis. Consistency: no substantial inconsistency was identified for this specific comparison or it was described in one trial; no additional downgrade on this basis. Applicability to the stated group: the conclusion applies to the stated participants and measured outcome; no additional downgrade on this basis. Potential publication bias: publication bias for this specific outcome was assessed only to a limited extent; no additional downgrade on this basis. Study methods: methodological limitations and incomplete formal assessment reduce confidence. |
| Volume of evidence | 1 trial |
| Sources | [4] |
In a small study, fatigue decreased in young adults with low vitamin D; the result cannot be extended to people with adequate status.
| Parameter | Data |
|---|---|
| Result | Change in fatigue score −3.3 versus −0.8 points; 72% versus 50% reported improvement. |
| Participants | 120 adults with fatigue, mean age 29 years, 25(OH)D below 20 ng/mL |
| Form | Single oral dose of vitamin D3 |
| Dose | 100,000 IU once |
| Dose basis | International units of vitamin D3 in one dose |
| Comparison | Placebo |
| Duration | 4 weeks |
| Confidence | low 2/4: Limitations of individual studies and incomplete formal assessment; no substantial inconsistency identified or only one study; conclusion limited to the stated population and outcomes; small sample, wide interval or imprecise estimate; full assessment not possible. |
| Volume of evidence | Named sources: 1 |
| Sources | [2] |
More details
Who the results apply to
The fatigue result applies to participants with low vitamin D levels. It cannot automatically be extended to people with adequate status. [2]
Sources
- Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults. https://www.nejm.org/doi/10.1056/NEJMoa2202106
- Effect of vitamin D3 on self-perceived fatigue: A double-blind randomized placebo-controlled trial. https://pubmed.ncbi.nlm.nih.gov/28033244/
- Effect of Long-term Vitamin D3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/32749491/
- Effect of vitamin D on cognitive decline: results from two ancillary studies of the VITAL randomized trial. https://www.nature.com/articles/s41598-021-02485-8
Methodology: Subpages evidence-led supplement pipeline v1